Therapeutic dose starts at 4mg. 8mg is one of the doses that had major weight loss. 12mg was better, but not by much. Some people think glucagon only kicks in at higher doses, but pre clinical data shows that you get glucagon activation at low doses.
Over time, you’ll find that your appetite returns, but that you keep losing weight.
Does the appetite always return under all doses?
Does the body get used to all doses?
One of the reasons I titrated up to 6, in addition to wanting to get to the 8-12 range that saw the most dramatic results in weight change and I’m guessing metabolic/anti inflmmatory change (aren’t a lot of the changes dose dependent?), is that I felt my appetite was back after a month of 4mg… Now after a month of 6mg still waiting for some equilibrium in terms of side effects…
If it continues I will just retreat to 4mg
Appetite returns, yes. If you browse GLP1 related forums, you’ll see posts about people panicking/complaining about lack of appetite surpression after being on a dose for awhile (mostly tirzepatide, semaglutide but this applies to all GLP1a) . They’re often worried about gaining the weight back since they’re eating more, but what ends up happening is that although they may not be losing more weight, they’re maintaining their weight loss.
I would increase the dose only on a weight loss plateau (4 weeks of no weight loss), not on loss of appetite suppression.
Your body gets used to a dose over time, if you’re talking about side effects . I’ve been on the same high dose for 4 months, and I’ve had 0 side effects on that dose, while slowly losing more weight. My appetite has been pretty normal during that period.
You can always monitor some changes via a metabolic panel. I saw my markers improve early when I was on only 4mg: decrease on A1c, Triglycerides, and better egfr.
I haven’t been losing weight slowly… I’ve been on the med for a little over 3 months and went from ~198 to ~162…
This might be part of the issue…
I increased the dose even while running through the weight, having dizziness etc
I may need to take a step back and think its working too well for me… and need to be more selective with titrating up…
I’m seeing the trials and they are talking about 12mg for mass weight loss when it was heading that way for me on low dosage…
I suspect that I take a lot of glycine is at issue… it has glp affects which can be additive I’m thinking and folks often take glycine with these meds
Thats good, having this conversation made it obvious to me what my next move should be, lol.
I just though I saw some dose dependent reports that made me want to shoot for the stars.
3 years ago, the obesity drug market was basically Ozempic. Today, it’s 9 drugs deep in late-stage. Here’s what each one actually adds:
Foundayo: latest oral GLP-1. approved April 1, 2026. Injections become optional.
Retatrutide: 24% weight loss at 48 weeks (Phase 2). Triple agonist.
CagriSema: less nausea than semaglutide. NDA filed December 2025.
Survodutide: GLP-1 + glucagon. Cuts liver fat alongside weight.
Amycretin: oral weekly. GLP-1 + amylin. Phase 2.
Petrelintide: amylin only. Phase 2 posted March 2026.
Mazdutide: China approved 2026. US Phase 3 ongoing.
Pemvidutide: obesity + MASH dual indication.
Monlunabant: CB1 inverse agonist. Phase 2.
The next pharma cycle may not be Novo vs Lilly. It’s shaping up as mechanism vs mechanism.
Source: https://x.com/agingroy/status/2045551011612500182?s=20
